Your browser doesn't support javascript.
loading
Allogeneic double-negative T cell therapy for relapsed acute myeloid leukemia patients post allogeneic hematopoietic stem cell transplantation: A first-in-human phase I study.
Tang, Baolin; Lee, Jong Bok; Cheng, Siqi; Pan, Tianzhong; Yao, Wen; Wang, Dongyao; Tu, Meijuan; Xiang, Zhiqiang; Chu, Xiandeng; Geng, Liangquan; Qiang, Ping; Teng, Pingping; Sun, Guangyu; Liu, Huilan; Wang, Jian; Schimmer, Aaron D; Yang, Liming; Sun, Zimin; Zhang, Li; Zhu, Xiaoyu.
Afiliação
  • Tang B; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Lee JB; Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Cheng S; Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei, China.
  • Pan T; Transplantation Department, Toronto General Hospital Research Institute, University Health Network, Toronto, Ontario, Canada.
  • Yao W; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Wang D; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Tu M; Department of Hematology, Huaibei People's Hospital, Huaibei, China.
  • Xiang Z; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Chu X; Blood and Cell Therapy Institute, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Geng L; Anhui Provincial Key Laboratory of Blood Research and Applications, Hefei, China.
  • Qiang P; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Teng P; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Sun G; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Liu H; R&D Center, WYZE Biotech Co., Ltd, Hangzhou, China.
  • Wang J; Cell Manufacturing Department, Ruichuang Biotechnology Co., Ltd, Shaoxing, China.
  • Schimmer AD; Department of Hematology, Lu'an Hospital Affiliated to Anhui Medical University, Lu'an, China.
  • Yang L; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Sun Z; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.
  • Zhang L; R&D Center, WYZE Biotech Co., Ltd, Hangzhou, China.
  • Zhu X; Cell Manufacturing Department, Ruichuang Biotechnology Co., Ltd, Shaoxing, China.
Am J Hematol ; 97(7): E264-E267, 2022 07.
Article em En | MEDLINE | ID: mdl-35385187
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas Limite: Humans Idioma: En Revista: Am J Hematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas Limite: Humans Idioma: En Revista: Am J Hematol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China